Most-Favored Entry Clauses in Drug-Patent Litigation Settlements: Reverse Payments and Anticompetitive Effects

›

Author: Keith M. Drake and Thomas G. McGuire

Position: Director, Greylock McKinnon Associates/Professor of Health Economics Emeritus, Department of Health Care Policy

Pages: 1-8

Linked as:


Document options

Extract

Most-Favored Entry Clauses in Drug-Patent Litigation Settlements: Reverse Payments and Anticompetitive Effects

No longer available (Autolink)

See the full content of this document